Literature DB >> 21818090

Alzheimer's therapy: a BACE in the hand?

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21818090     DOI： 10.1038/nm0811-932

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals.

Authors:  Soong Ho Kim; Paul E Fraser; David Westaway; Peter H St George-Hyslop; Michelle E Ehrlich; Sam Gandy
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

2.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.

Authors:  Jasvinder K Atwal; Yongmei Chen; Cecilia Chiu; Deborah L Mortensen; William J Meilandt; Yichin Liu; Christopher E Heise; Kwame Hoyte; Wilman Luk; Yanmei Lu; Kun Peng; Ping Wu; Lionel Rouge; Yingnan Zhang; Robert A Lazarus; Kimberly Scearce-Levie; Weiru Wang; Yan Wu; Marc Tessier-Lavigne; Ryan J Watts
Journal:  Sci Transl Med       Date:  2011-05-25       Impact factor: 17.956

4.  Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.

Authors:  Y Joy Yu; Yin Zhang; Margaret Kenrick; Kwame Hoyte; Wilman Luk; Yanmei Lu; Jasvinder Atwal; J Michael Elliott; Saileta Prabhu; Ryan J Watts; Mark S Dennis
Journal:  Sci Transl Med       Date:  2011-05-25       Impact factor: 17.956

5.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Authors:  R Vassar; B D Bennett; S Babu-Khan; S Kahn; E A Mendiaz; P Denis; D B Teplow; S Ross; P Amarante; R Loeloff; Y Luo; S Fisher; J Fuller; S Edenson; J Lile; M A Jarosinski; A L Biere; E Curran; T Burgess; J C Louis; F Collins; J Treanor; G Rogers; M Citron
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

6.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

Review 7.  The secretases: enzymes with therapeutic potential in Alzheimer disease.

Authors:  Bart De Strooper; Robert Vassar; Todd Golde
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

8.  beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein.

Authors:  Hidekuni Yamakawa; Sosuke Yagishita; Eugene Futai; Shoichi Ishiura
Journal:  J Biol Chem       Date:  2009-11-19       Impact factor: 5.157

9.  Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039.

Authors:  Takao Yoshimizu; Shigeyuki Chaki
Journal:  Biochem Biophys Res Commun       Date:  2004-03-05       Impact factor: 3.575
  9 in total
  2 in total

1.  Animal models and conserved processes.

Authors:  Ray Greek; Mark J Rice
Journal:  Theor Biol Med Model       Date:  2012-09-10       Impact factor: 2.432

Review 2.  Systematic reviews of animal models: methodology versus epistemology.

Authors:  Ray Greek; Andre Menache
Journal:  Int J Med Sci       Date:  2013-01-11       Impact factor: 3.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.